FASTIN
LOE ApproachingNDAORALCAPSULE
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FASTIN is an oral capsule small-molecule drug approved in 1973 by GSK. The specific indication and mechanism of action are not disclosed in available data, but the product is classified as a standard NDA small-molecule therapeutic. This legacy product has been in the market for over 50 years.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting team focus is shifting toward retention strategies and potential lifecycle extension.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
Started Jul 2026
60 enrolled
Melanoma (Skin Cancer)
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Started Jul 2026
130 enrolled
Diabetes Mellitus, Type 2Diabetes MelletusGlucose Metabolism Disorders+13 more
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions
Started May 2026
30 enrolled
Healthy Adults
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Started Dec 2025
20 enrolled
Type 2 Diabetes Mellitus (T2DM)
Worked on FASTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.